



Figure 4A

0 hr
 PMA ACE
 (100 nM) (3 mg/ml)


Involucrin




p63α




Loricrin




p-EGFR^{Y1068}



K10



EGFR



β-actin




Figure 4B





Figure 4C


PMA
(100 nM) ACE
(3 mg/ml)

0 0.5 1 2 6 0.5 1 2 6 hr



p-EGFR^{Y1068}



EGFR




p-AKT^{T308}



p-PKC β II^{S660}



PKC β II




β -actin




Figure 4D

ACE (3 mg/ml)	vehicle				TH1020 (2 μ M)				Osimertinib (1 μ M)				
	—	1	3	6	—	1	3	6	—	1	3	6	hr

p-AKT^{T308}




AKT



p-PKC β II^{S660}



PKC β II



β -actin



Figure 5A





Figure 5B

veh	PMA		ACE		ACE		Osi		Osi + PMA		Osi + ACE		Osi + ACE		hr
	(100 nM)		(1 mg/ml)		(3 mg/ml)		(1 μM)				(1 mg/ml)		(3 mg/ml)		
36	24	36	24	36	24	36	24	36	24	36	24	36	24	36	

Involucrin



β-actin

